In the pilot trial, 11 HLA-A201-positive patients with AML or ALL who had received alloSCT were treated with adoptive transfer of donor-derived, in vitro expanded WT-1 RMF peptide-specific CD8+ T-cells. This evidence concerns the gene CD8A and acute lymphoblastic leukemia.